Literature DB >> 15536636

A sensitive, rapid and specific determination of midazolam in human plasma and saliva by liquid chromatography/electrospray mass spectrometry.

Oscar Quintela1, Angelines Cruz, Marta Concheiro, Ana de Castro, Manuel López-Rivadulla.   

Abstract

A rapid, sensitive and selective liquid chromatography/electrospray mass spectrometry (LC/ES-MS) method was developed for the quantitative determination of the anaesthetic benzodiazepine midazolam (MID) in human saliva and plasma from patients undergoing anesthesia procedures. Biological samples spiked with diazepam-d5, the internal standard, were extracted into diethyl ether. Compounds were separated on a Xterra RP18 column using a mobile phase of acetonitrile/formic acid 0.1% at a flow rate of 0.25 mL/min under a linear gradient. Column effluents were analyzed using MS with an ES source in the positive ionization mode. Calibration curves were linear in the concentration ranges of 1-250 and 0.2-25 ng/mL in plasma and saliva, respectively. The limits of detection were 0.5 ng/mL in plasma and 0.1 ng/mL in saliva, using a 0.5-mL sample volume. The recoveries of the spiked samples were above 65%. The method was applied to ten real samples from patients undergoing midazolam treatment. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536636     DOI: 10.1002/rcm.1719

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  7 in total

Review 1.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

2.  Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam.

Authors:  Stephanie Katzenmaier; Christoph Markert; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2010-08-03       Impact factor: 2.953

3.  Concentration effect relationship of CYP3A inhibition by ritonavir in humans.

Authors:  Christine Eichbaum; Marianna Cortese; Antje Blank; Jürgen Burhenne; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2013-06-09       Impact factor: 2.953

4.  Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.

Authors:  Ines Fuchs; Verena Hafner-Blumenstiel; Christoph Markert; Jürgen Burhenne; Johanna Weiss; Walter Emil Haefeli; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2012-09-12       Impact factor: 2.953

5.  Development and validation of a sensitive assay for analysis of midazolam, free and conjugated 1-hydroxymidazolam and 4-hydroxymidazolam in pediatric plasma: Application to Pediatric Pharmacokinetic Study.

Authors:  Ganesh S Moorthy; Harini Jogiraju; Christina Vedar; Athena F Zuppa
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-09-28       Impact factor: 3.205

Review 6.  Oral fluid testing for drugs of abuse.

Authors:  Wendy M Bosker; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-09-10       Impact factor: 8.327

7.  Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity.

Authors:  Sabrina T Wiebe; Andreas D Meid; Gerd Mikus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-08-08       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.